ASBPW executed a massive 1-for-40 reverse stock split while experiencing severe operational losses that increased 15-fold and a dramatic 80% decline in total assets.
The reverse stock split from 48.9 million to 5 million shares outstanding combined with $17.4 million in non-affiliate market value suggests the company is fighting delisting threats from low share prices. The removal of specific manufacturing partnership details with Glatt and clinical trial information indicates potential setbacks in their drug development pipeline.
The company's financial position deteriorated dramatically with operating losses exploding from -$1.2M to -$19.4M while total assets collapsed 80% from $6.7M to $1.3M, though current assets did increase substantially to $1.3M. While stockholders' equity improved by reducing losses from -$15.6M to -$6.4M and liabilities were cut in half, the massive increase in R&D expenses (+540%) and operating cash flow burn rate doubling to -$4.9M signals an unsustainable cash consumption trajectory. The 95% reduction in share buybacks from $284.9M to $13.8M indicates severely constrained capital allocation flexibility.
Current assets grew 2762.4% — improving short-term liquidity or inventory/receivables build.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
R&D investment increased 540% — signals commitment to future product development, though near-term margin impact.
Operating cash flow fell 139.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Net income declined 95.3% — review whether driven by operations, interest costs, or non-recurring items.
Buyback activity reduced 95.2% — capital being redeployed elsewhere or cash conservation underway.
Total assets contracted 80.5% — asset sales, write-downs, or balance sheet optimization underway.
Equity base grew 59% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Current liabilities reduced — improved short-term financial position and working capital health.
Liabilities reduced 50.8% — deleveraging improves balance sheet strength and financial flexibility.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →